Bafna Pharmaceuticals (Small Cap - Potential Multibagger) Share Target 2026, 2027 To 2035
|
Bafna Pharmaceuticals Limited |
|||
|
Price: ₹174.58 (-10%) | ||
| 52 Week Low: ₹72.01 52 Week High: ₹213.36 |
|||
| Market Capital: 333.77 Crore (Small-cap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Bafna Pharmaceuticals Stock Comparison: Bafna Pharmaceuticals vs Krebs Biochemicals & | Bafna Pharmaceuticals vs Bal Pharma | Bafna Pharmaceuticals vs Mangalam Drugs & Organics | Bafna Pharmaceuticals vs SMS Lifesciences | Bafna Pharmaceuticals vs Vaishali Pharma | Bafna Pharmaceuticals vs AAREYDRUGS |
|||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Bafna Pharmaceuticals Share Price Target For 2026
- 1.1.1: Bafna Pharmaceuticals Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Bafna Pharmaceuticals Share Price Target For 2027
- 1.2.1: Bafna Pharmaceuticals Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Bafna Pharmaceuticals Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Bafna Pharmaceuticals Brief Company Overview
- 4: Bafna Pharmaceuticals Financial Performance
- 4.0.1: Is Bafna Pharmaceuticals A Good Buy For Long Term?
Bafna Pharmaceuticals, a Small Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 138.5% returns in 1-year with 0.2% profit margin, making it a potential Multibagger.
To predict the Bafna Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Bafna Pharmaceuticals Share Price Target For 2026
The line chart displays the monthly closing prices of Bafna Pharmaceuticals with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bafna Pharmaceuticals shares in 2026, see the table below.
Bafna Pharmaceuticals Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 209.87 (+20.21%) | Volatility: ATR T2 |
| 2026 Target 2 | 195.76 (+12.13%) | Volatility: ATR T1 |
| 2026 Target 1 | 179.45 (+2.78%) | Volatility: BB Upper |
| Current Price | 174.58 | Bafna Pharmaceuticals's share price as of 09 Jun 2026 |
| Stop Loss 1 | 162.18 (-7.11%) | Trend: EMA9 |
| Stop Loss 2 | 153.40 (-12.14%) | Volatility: ATR S1 |
| Stop Loss 3 | 152.38 (-12.72%) | 38.20% Weekly Fib Retrace |
Short-Term Technical Outlook
Current Technical Position: Bafna Pharmaceuticals is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹134.83 serves as the nearest technical reference point.
Historical Returns: 3-month: +81.3% | 6-month: +38.27% | 1-year: +138.52%
Bafna Pharmaceuticals Share Price Target For 2027
The line chart displays the monthly closing prices of Bafna Pharmaceuticals with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bafna Pharmaceuticals shares in 2027, see the table below.
Bafna Pharmaceuticals Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 209.87 (+20.21%) | Volatility: ATR T2 |
| 2027 Target 2 | 195.76 (+12.13%) | Volatility: ATR T1 |
| 2027 Target 1 | 179.45 (+2.78%) | Volatility: BB Upper |
| Current Price | 174.58 | Bafna Pharmaceuticals's share price as of 09 Jun 2026 |
| Stop Loss 1 | 162.18 (-7.11%) | Trend: EMA9 |
| Stop Loss 2 | 153.40 (-12.14%) | Volatility: ATR S1 |
| Stop Loss 3 | 152.38 (-12.72%) | 38.20% Weekly Fib Retrace |
Long-Term Technical Outlook
52-Week Range Analysis: Bafna Pharmaceuticals is currently trading at 72.6% of its 52-week range (₹72.01 - ₹213.36).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +138.52% | 3-year: +41.7% | 5-year: +23.53%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Bafna Pharmaceuticals Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹174.58 | ||
| 2026 | ₹152.82 | -12.464199793791% | ₹155.11 |
| 2027 | ₹237.56 | +55.450857217642% | ₹241.12 |
| 2028 | ₹350.07 | +47.360666778919% | ₹355.32 |
| 2029 | ₹432.54 | +23.558145513754% | ₹439.03 |
| 2030 | ₹565.45 | +30.727793961252% | ₹573.93 |
| 2031 | ₹653.29 | +15.534530020338% | ₹663.09 |
| 2032 | ₹906.61 | +38.776041268043% | ₹920.21 |
| 2033 | ₹1,150.44 | +26.894695624359% | ₹1,167.70 |
| 2034 | ₹1,466.18 | +27.445151420326% | ₹1,488.17 |
| 2035 | ₹1,705.54 | +16.32541707021% | ₹1,731.12 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Bafna Pharmaceuticals Brief Company Overview
Bafna Pharmaceuticals Limited: A Pharmaceutical Powerhouse Established in 1981, Bafna Pharmaceuticals Limited has emerged as a leading manufacturer and exporter of finished pharmaceutical formulations in India. Diverse Product Portfolio Delayed and sustained release...
tablets Chewable tablets Orally disintegrating tablets Industry Reputation and Commitment Bafna Pharmaceuticals has earned a strong reputation in the industry for its quality products and commitment to innovation. The company is a subsidiary of SRJR Lifesciences LLP, ensuring stability and growth. Global Reach Bafna Pharmaceuticals exports its products to various countries, establishing a presence in the global pharmaceutical market.Bafna Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 189.32 Crore | Market valuation of Bafna Pharmaceuticals's shares. |
| Revenue (TTM) | 143.8 Crore | Total revenue generated by Bafna Pharmaceuticals over the past twelve months. |
| Net Income (TTM) | +27.32 Lakh | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -0.7% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 0.19% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-20.6% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
30.17 | Company's total debt divided by total shareholder equity. |
| Total Debt | 24.38 Crore | Sum of Bafna Pharmaceuticals's current & long-term financial obligations. |
| Total Cash | 1.39 Crore | Total amount of liquid funds available to Bafna Pharmaceuticals. |
| Beta | 0.46 | Beta is less than 1 indicating that the Bafna Pharmaceuticals's price is less volatile than the market. |
Is Bafna Pharmaceuticals A Good Buy For Long Term?
Bafna Pharmaceuticals, a small-cap stock with a market capitalization of ₹189.32 crore, presents a mixed picture for long-term investors. While its revenue of ₹143.8 crore is substantial, a meager ₹27.32 lakh net profit (0.19% margin) and a significant debt of ₹24.38 crore (Q1 2024-25) raise serious concerns. Negative returns over the past 3 months (-6.98%), 6 months (-15.62%), and year-to-date (-13.05%) further fuel caution. Although past 5-year returns show a considerable increase (592.64%), the recent performance is worrying. Overall, it's not a good buy for the long term given the current financials. Further investigation into the reasons behind the declining revenue and profitability is warranted before considering any investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
